Results 191 to 200 of about 11,226 (207)

Daratumumab

Reactions Weekly, 2018
  +4 more sources

Daratumumab

Reactions Weekly, 2017
openaire   +2 more sources

Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel

Critical Reviews in Oncology/Hematology, 2022
Corrado Girmenia, Michele Cavo, Francesco Di Raimondo   +2 more
exaly  

Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma

European Journal of Haematology, 2023
Leyla Shune, Meera Mohan
exaly  

Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma

Clinical Infectious Diseases, 2021
Soon Kyu Lee, Pil Soo Sung, Sung-Soo Park   +2 more
exaly  

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia

Oncology and Therapy, 2021
Matthew Streetly, Vadim V Ptushkin, Jon Ukropec   +2 more
exaly  

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

ESMO Open, 2021
F Duca, I Simonitsch-Klupp, D Bonderman   +2 more
exaly  

Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab

Clinical Lymphoma, Myeloma and Leukemia, 2020
Justin R Arnall, Daniel L Thompson, Allison L Martin   +2 more
exaly  

Daratumumab: A review of current indications and future directions

Seminars in Oncology, 2022
Elizabeth Hill, Dickran Kazandjian
exaly  

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Lancet, The, 2016
Sagar Lonial, Saad Z Usmani, Ajai Chari   +2 more
exaly